EMA Approves BioNTech’s COVID-19 Vaccine Manufacturing Site
EMA has approved the manufacturing of drug product for BioNTech’s COVID-19 vaccine, BNT162b2, at BioNTech’s manufacturing site located in Marburg, Germany.
BioNTech announced on March 26, 2021 that the European Medicines Agency (EMA) has approved the manufacturing of drug product for its COVID-19 vaccine, BNT162b2, at BioNTech’s manufacturing site located in Marburg, Germany.
According to a company press release, EMA has approved the production of the vaccine’s messenger RNA (mRNA) at the Marburg facility, meaning the first batches of the vaccine can be delivered to the company’s partner sites for sterile fill/finish, then distributed to the European Union and other countries. The initial batches manufactured at the Marburg site are set to be delivered during the second half of April 2021.
“A key factor in the expansion of our manufacturing network has been the set-up of this new manufacturing site in Marburg, Germany,” BioNTech said in the press release. “BioNTech plans to be able to produce up to 250 million doses of BNT162b2 in the first half of 2021.”
Source: BioNTech
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
